A large retrospective study of the UNOS database advances that elevated troponin I in selected cardiac donors is NOT associated with various adverse events. The conclusion is likely to stimulate heated discussions.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Coronary Disease - Other
Donor Troponin and Survival After Cardiac Transplantation. An Analysis of the United Network of Organ Sharing Registry
June 25, 2016
April 3, 2016
In a propensity-matched analysis, Rosenblum and colleagues found that hybrid revascularization as compared with coronary artery bypass grafting with either single or bilateral internal mammary artery grafts was superior in terms of secondary short-term outcomes (e.g.
March 11, 2016
The authors provide an excellent overview of the rationale for screening all patients with a new diagnosis of cardiomyopathy for coronary artery disease. This rationale includes the following:
February 18, 2016
An Editorial suggesting that atheroma is here to stay...
November 17, 2015
The authors report on the extended follow-up of Courage Trial patients for up to 15 years. In this trial, patients with chronic stable angina were randomized to medical therapy alone versus PCI plus medical therapy. At extended follow-up, there was no difference in overall survival between the two treatment strategies.
July 6, 2015
This video shows how to modify the trap-door technique, commonly used in the arterial switch operation in children, in order to re-implant the coronary ostia in adult patients undergoing aortic root replacement.
April 2, 2015
Repair of this congenital defect in 34 pts was associated with no early mortality and substantial improvement in LV function (EF, shortening fraction, LVEDD). No postoperative circulatory support was required.
February 4, 2015
104 patients with class III or IV angina who were not candidates for revascularization were randomized to a sham procedure or to placement of a coronary sinus narrowing device. 35% of those in the device group improved their angina 2 classes, and 71% improved by 1 class, compared to 15% and 42% in the sham group. Quality of life improved more in th
December 18, 2014
This randomized trial in New Zealand assigned smokers who wished to quit to either nicotrine replacement therapy or cytisine therapy.
November 28, 2014
Shanker Vedantam interviews Jason Hockenberry, an economist at Emory University, regarding recent research into patient behavior following PCI or CABG. CABG patients were more likely to quit smoking after intervention for CAD. This may be a result of the magnitude of the intervention, and has implications for improving smoking cessation programs.